Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aeglea Biothera (AGLE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 79,947
  • Shares Outstanding, K 16,450
  • Annual Sales, $ 4,630 K
  • Annual Income, $ -21,700 K
  • 36-Month Beta 3.09
  • Price/Sales 16.81
  • Price/Cash Flow 0.00
  • Price/Book 1.24

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.95 +64.75%
on 08/23/17
5.12 -5.08%
on 09/21/17
+1.76 (+56.77%)
since 08/22/17
3-Month
2.81 +72.95%
on 08/17/17
5.12 -5.08%
on 09/21/17
+0.91 (+23.04%)
since 06/22/17
52-Week
2.81 +72.95%
on 08/17/17
10.34 -53.00%
on 11/21/16
-1.56 (-24.30%)
since 09/22/16

Most Recent Stories

More News
Aeglea BioTherapeutics Doses Two Patients in Repeat Dose Part of Phase 1/2 Clinical Trial for the Treatment of Arginase 1 Deficiency

Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today...

AGLE : 4.86 (+2.75%)
Aeglea BioTherapeutics to Present at the 2017 Wells Fargo Healthcare Conference

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today...

AGLE : 4.86 (+2.75%)
WFC : 54.25 (+0.35%)
Aeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2017 Financial Results

Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today...

AGLE : 4.86 (+2.75%)
Aeglea BioTherapeutics Appoints James Wooldridge, M.D. as Chief Medical Officer

Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today...

AGLE : 4.86 (+2.75%)
LLY : 83.91 (+0.70%)
Endo Asked to Withdraw Pain Drug-Opana ER by FDA, Stock Down

Endo International plc (ENDP) received a huge setback when the FDA directed the company to voluntarily remove its opioid pain medication Opana ER (oxymorphone hydrochloride extended release) from the market...

AGLE : 4.86 (+2.75%)
ENDP : 8.66 (-1.59%)
VVUS : 0.96 (unch)
MEIP : 2.75 (+0.36%)
Mallinckrodt (MNK) Commences Phase III Study of StrataGraft

Mallinckrodt plc (MNK) has enrolled the first patient in phase III study, assessing StrataGraft regenerative skin tissue for promoting autologous skin regeneration in patients with thermal burns.

AGLE : 4.86 (+2.75%)
VVUS : 0.96 (unch)
MEIP : 2.75 (+0.36%)
MNK : 34.83 (-0.09%)
Kite Pharma (KITE) Releases Data on Lead Drug for Leukemia

Kite Pharma, Inc. (KITE) announced results from phase I trial, ZUMA-3, on lead candidateKTE-C19 (axicabtagene ciloleucel) in adults with high burden relapsed/refractory acute lymphoblastic leukemia (r/r...

AGLE : 4.86 (+2.75%)
VVUS : 0.96 (unch)
MEIP : 2.75 (+0.36%)
KITE : 179.30 (-0.04%)
Aeglea BioTherapeutics Announces Proposed Public Offering of Common Stock

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today...

AGLE : 4.86 (+2.75%)
Alnylam's Givosiran Gets Breakthrough Therapy Status by FDA

Alnylam Pharmaceuticals, Inc. (ALNY) announced that it has received Breakthrough Therapy designation from the FDA for pipeline candidate givosiran (ALN-AS1), for the prophylaxis of attacks in patients...

AGLE : 4.86 (+2.75%)
VVUS : 0.96 (unch)
ALNY : 113.80 (+0.78%)
MEIP : 2.75 (+0.36%)
Ligand (LGND) Signs Licensing Deal with xCella Biosciences

Ligand Pharmaceuticals Incorporated (LGND) announces it has entered into a worldwide license agreement with drug discovery company xCella Biosciences, Inc.

AGLE : 4.86 (+2.75%)
LGND : 135.55 (-0.19%)
VVUS : 0.96 (unch)
MEIP : 2.75 (+0.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

See More

Business Summary

Aeglea BioTherapeutics, Inc. is a biotechnology company which is engaged in developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. Its portfolio of products consists of AEB1102, AEB3103, AEB2109 and AEB4104 which are in different clinical...

See More

Support & Resistance

2nd Resistance Point 5.07
1st Resistance Point 4.96
Last Price 4.86
1st Support Level 4.73
2nd Support Level 4.61

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.